Optimizing Immune Checkpoint Inhibitor/Targeted Therapy Combination Adverse Event Management

Get personalized guidance on managing immune-related AEs for your patients with our newly updated Interactive Decision Support Tool adapted from the latest NCCN guidelines. Then, gain multidisciplinary insights into managing toxicities from ICI/targeted therapy combination regimens with an expert text module and downloadable slides.

Share

Program Content

Activities

AEs With ICI/Targeted Tx
Expert Strategies for Managing Adverse Events With Combination Immune Checkpoint Inhibitor/Targeted Therapy
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: May 25, 2023

Expires: May 24, 2024

Activities

AEs With Combo ICI Tx
Managing Adverse Events With Combination Immune Checkpoint Inhibitor/Targeted Therapy
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 19, 2023

Faculty

cover img faculity

Eric Jonasch, MD

Professor, Department of GU Medical Oncology
UT MD Anderson Cancer Center 
Houston, Texas

cover img faculity

Kathleen N Moore, MD, MS

Virginia Kerley Cade Chair in Developmental Therapeutics
Deputy Director
Cancer Therapeutics Co-Director
Stephenson Cancer Center at the University of Oklahoma
ASCO BOD
Oklahoma City, Oklahoma

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca, Eisai, Merck Sharp & Dohme LLC, and Regeneron Pharmaceuticals, Inc.

AstraZeneca

Eisai

Merck Sharp & Dohme, LLC

Regeneron Pharmaceuticals, Inc